BTIG raised the firm’s price target on Haemonetics (HAE) to $88 from $85 and keeps a Buy rating on the shares after the company beat expectations across all business segments, reset Hospital guidance to “an achievable level,” and raised the total sales outlook for FY26. Arguing that this quarter’s execution was a positive lift for credibility on both operations and messaging, the firm thinks shares can continue “a gradual recovery from here,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics rises 26.1%
- Haemonetics narrows FY26 adjusted EPS view to $4.80-$5.00 from $4.70-$5.00
- Haemonetics reports Q2 adjusted EPS $1.27, consensus $1.11
- Haemonetics (HAE) Q2 Earnings Cheat Sheet
- Haemonetics: Strategic Adjustments and Growth Potential Justify Buy Rating Despite Revenue Challenges